AstraZeneca: Farxiga gets priority review for heart failure
(CercleFinance.com) - The US Food and Drug Administration (FDA) has granted priority review designation to AstraZeneca's diabetes drug Farxiga for patients with heart failure, the Anglo-Swedish drugmaker said on Monday.
The FDA has accepted a supplemental new drug application for Farxiga to reduce the risk of cardiovascular death or the worsening of heart failure in adults with heart failure with reduced ejection fraction with and without type-2 diabetes, it said.
The FDA will make its final decision in the second quarter of 2020.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The FDA has accepted a supplemental new drug application for Farxiga to reduce the risk of cardiovascular death or the worsening of heart failure in adults with heart failure with reduced ejection fraction with and without type-2 diabetes, it said.
The FDA will make its final decision in the second quarter of 2020.
Copyright (c) 2020 CercleFinance.com. All rights reserved.